
The departments of Health and Human Services and Defense will pay Janssen Pharmaceutical Companies of Johnson & Johnson $1 billion to manufacture 100 million doses of its COVID-19 vaccine candidate for use in clinical trials, or to vaccinate Americans if authorized by the Food and Drug Administration.